A bioengineered probiotic for resetting immune function in rheumatoid arthritis

Active Grant Awarded

Award ID
R44AR087173
Recipient
Awarding agency
Obligated
$306,341

Award facts

Completion date 26% complete
Place of performance
Seattle, WA 98122, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute of Arthritis and Musculoskeletal and Skin Diseases, awarded Virtici LLC of Seattle, Washington $306,341 on August 26, 2026, under Assistance Listing 93.846, Arthritis, Musculoskeletal and Skin Diseases Research. Grant R44AR087173 funds the commercialization of VTC-B35, a bioengineered, orally administered probiotic therapy for long-term disease remission in rheumatoid arthritis. The project develops an oral immunotherapeutic that regulates auto-antigen-specific regulatory T cells (Tregs) and B cells (Bregs) to provide disease-specific tolerance, with the stated aim of preventing relapse without systemic immunosuppression. The assistance type is a grant, with $306,341 obligated and a completion date of July 31, 2027. Performance takes place in Seattle, WA 98122.

Description

Abstract
Our goal is to commercialize VTC-B35 as a novel, orally administered therapy for long-term disease remission of rheumatoid arthritis (RA). RA is a chronic, systemic inflammatory disorder affecting up to 1% of the US POPULATION1-3. While many organs are affected, the main targets of RA are synovial joints. As the disease progresses, approximately half of RA patients become DISABLED6. RA patients also face higher unemployment and double the risk of depression of the general POPULATION9. Treatment of RA remains a significant unmet medical need. Despite the advent of a number of effective but costly biologic therapies, less than half of RA patients achieve sustained remission, with many non-responsive or experiencing RELAPSE10 . Further, tolerability of biologics is limited by immunosuppressive side effects, such as increased risk of serious infections, cancer and, in rare instances, neurological COMPLICATIONS11-14 therapies that redirect immune responses to produce immune tolerance instead of inflammation have potential to treat the cause rather than the symptoms of disease, and so represent superior treatments for RA. For these reasons, we are developing an oral immunotherapeutic that regulates auto-antigen specific regulatory T cells (TREGS) and B cells (BREGS) to provide disease-specific tolerance. This approach has the potential to 1) "switch off" the immune response against the patient's own tissues specific to RA in an enduring manner, and; 2) maximally balance the relationships between effector cells of different lineages to prevent relapses of inflammation. As such, our approach will provide patients long-term remission and increased safety without systemic immunosuppression. Our team recently demonstrated that oral administration of a probiotic bacterial strain expressing the cytokine IL-35 effectively induced treg cells, reduced disease severity, and generated a tolerogenic response in the mouse model of CIA22. Building from this initial work, we have engineered a clinical strain of the probiotic yeast S. Boulardii (termed VTC-B35) that expresses human IL-35 from a genome-integrated operon. The use of S. Boulardii allows US to leverage a well-accepted, gras (generally regarded as safe) probiotic strain with unique immune regulation, protein expression, and protein processing attributes. This application is designed to advance VTC-B35 towards the clinic by establishing its manufacturing, therapeutic activity, and animal safety. Successful commercialization of VTC-B35 will ultimately provide a profound front-line medical advancement in the treatment of RA, and potentially other autoimmune diseases as well.

Quick answers

Who received award R44AR087173?

R44AR087173 was awarded to Virtici LLC by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on August 26, 2026.

How much is award R44AR087173 worth?

$306,341 has been obligated on R44AR087173.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award